Musculoskeletal Amyloidosis Imaging

Anatomy

The most common joints involved in musculoskeletal amyloidosis include the shoulder and pelvic girdles, elbow, and wrist.[8] Soft tissue infiltration of amyloid into the shoulder myofibrillar tissues may manifest as hypertrophy of musculature with concomitant weakness and pain in an elderly patient with chronic illness. The cross-sectional imaging features of shoulder involvement are summarized by the "shoulder-pad" sign, which describes the counterintuitive finding of muscular hypertrophy in the setting of functional loss in this patient demographic.[12]

One of the most common presentations of musculoskeletal amyloidosis manifests as a late onset of carpal tunnel syndrome. Amyloid-related carpal tunnel syndrome is typically associated with the senescent type ATTR protein, which reflects systemic involvement, and can be a prognosticator of future myocardial involvement.[5] This presentation can also be seen in AB2M dialysis-related amyloidosis, which is seen in 31% of those undergoing long-term treatment.[13][7] 

The flexor tendons of the hand, wrist, and adjacent synovium become hypertrophied as amyloid is deposited into the myofibrillar tissues and may subsequently infiltrate into surrounding structures. The median nerve may appear compressed on cross-sectional imaging, and bony erosions are common. Paradoxical T2 signal loss of the median nerve may be seen on MRI, which is usually increased in signal in other forms of carpal tunnel syndrome.[5] These findings are seen in the radiographic images for patient 4.

Dialysis-related musculoskeletal amyloidosis is seen in approximately 30% of older patients undergoing long-term treatment, where the duration of dialysis dependence and prevalence of amyloidosis appear to be positively correlated.[5][9][14] This form of amyloidosis is typically associated with the AB2M subtype and manifests as soft tissue calcifications, extensive osseous destruction, and bilateral polyarthropathy, which may mimic various spondyloarthropathies.[10] 

Anatomic involvement includes the shoulder and hip girdles, as well as the carpal bones. Radiographic imaging may demonstrate lucent osseous lesions with peripheral sclerosis. CT imaging helps evaluate the degree of osseous erosion and the extent of soft tissue calcifications. MRI evaluation of the joints may show low T1 and T2 signals and minimal enhancement. Typical ultrasound appearance includes discontinuous hypertrophy of the tendons and adjacent synovium.[5]

Plain Films

The plain film is critical for the initial evaluation of any musculoskeletal complaint, especially in a patient with suspected or known amyloidosis. Plain film appearances of musculoskeletal amyloidosis include osseous erosions, osteopenia, well-defined lytic lesions, bone marrow infiltration, and pathologic fracture, as seen in the plain film images for patients 2 and 3. Affected joints may display subchondral cysts and calcification of adjacent soft tissues, highlighted in the plain film images for patients 3 through 5.[8][14]

Computed Tomography

The most common CT manifestations of amyloidosis involving bony structures include osteopenia, osseous erosions, well-defined lytic lesions, and bone marrow infiltration--all of which can lead to pathologic fractures--as seen in the CT images for patients 3 and 5. Affected joints may exhibit subchondral cysts, adjacent hypertrophy of soft tissues, and osteopenia.[8] 

Soft tissues may also demonstrate fine calcification, as seen in the CT images for patient 2. The "shoulder pad" sign can be in hypertrophied shoulder musculature, secondary to myofibrillar amyloid deposition, which is more commonly seen in AL amyloidosis. A CT-guided biopsy is useful for tissue sampling of suspected osseous amyloid. Imaging surveillance of suspected amyloid deposits is also a useful strategy, as seen in the CT images for patient 1. Dual-energy CT is infrequently used to assess for crystal deposition diseases, such as monosodium urate and calcium pyrophosphate, as seen in the CT images for patient 5.[15][16]

Magnetic Resonance

Magnetic resonance imaging (MRI) is useful for evaluating the structure and soft tissue characteristics of nerves, soft tissues, articular surfaces, and tendons.[5] A frequently encountered soft tissue manifestation of periarticular musculoskeletal amyloidosis seen on MRI is that of a tenosynovial giant cell tumor mimic (formerly PVNS) without the accompanying susceptibility artifacts to suggest a recurrent hemorrhagic process. These mimics appear as T1 and T2 hypointense lesions with mild to moderate contrast enhancement without significant blooming on susceptibility-weighted imaging.[12] 

It is an important consideration that both tenosynovial giant cell tumor and amyloidosis can coexist simultaneously, as seen in the MRI images for patient 5. The "shoulder pad" sign is also visible in hypertrophied shoulder musculature due to myofibrillar amyloid deposition. In amyloid-related carpal tunnel syndrome, paradoxical T2 signal loss of the median nerve may be seen on MRI, which is expected to demonstrate increased signal with other forms of carpal tunnel syndrome. The MRI manifestations of amyloid-related carpal tunnel syndrome can be seen in the MRI images for patient 4.[5] 

Imaging manifestations of tenosynovitis appear as an increased fluid signal on T2 and STIR sequences. Further examples of musculoskeletal amyloid MR imaging manifestations can be seen in the MRI images for patient images 2, 3, and 5.

Ultrasonography

Ultrasound can be used to evaluate musculoskeletal complaints in a patient with suspected or known amyloidosis. Ultrasound is useful as a screening tool for the presence of a mass, can provide additional information regarding mass composition, such as fluid or microcalcification, and may evaluate the integrity of structures, such as nerves and tendons, with both static and dynamic acquisition. Soft tissue infiltration, calcification, and joint effusions may be visible.[5] 

Ultrasound can also monitor known or new soft tissue lesions, as seen in the ultrasound images for patient 2. Ultrasound-guided biopsy is a valuable intervention for tissue sampling of suspected soft tissue amyloidomas.

Nuclear Medicine

Fluorodeoxyglucose positron emission tomography is the primary scintigraphic imaging technique. It is useful in the detection, localization, assessment of treatment response, and surveillance of amyloid plaques, as seen in the FDG PET/CT images for patient 2. Some common areas of uptake include the shoulder and pelvic girdles, the elbow, and the wrist. Myofibrillar amyloid deposition within the shoulder musculature will demonstrate avid uptake, complementing the "shoulder pad" sign, which may also be seen on other cross-sectional modalities. Soft tissue amyloid plaques will also demonstrate uptake.[9] 

Although less frequently used, radionuclide bone scintigraphy using technetium-99m methylene diphosphonate may demonstrate uptake into affected osseous structures.[14]

Patient Positioning

There are no specific patient positioning requirements to optimize the imaging of amyloidosis. Positioning that maximizes patient comfort coupled with using standardized views is considered sufficient. Minimizing unnecessary radiation dosage to the patient can be achieved by reducing photon energy and quantity, optimizing the source-to-object distance, maximizing collimation and filtration, and ensuring the patient is within the isocenter of the field of view.[17][18] 

Radiographic positioning should correspond to the standard imaging plane view types associated with the specific area of interest, such as anterior-posterior and lateral views of the tibia and fibula.[19] The optimal patient positioning for cross-sectional imaging (such as CT, MRI, and FDG-PET) corresponds to the supine positioning of the patient on the gantry isocenter.[17][18] 

Optimization of patient positioning during the use of ultrasound prioritizes patient comfort while positioning the area of interest in such a way as to accommodate the probe and planned sonographic window.[20]

Clinical Significance

Musculoskeletal amyloidosis (MA) is a complex disease process that tends to be systemic but sporadic in involvement and frequently poses a diagnostic challenge. MA usually manifests as a secondary disease process but can also present as a primary process. The most common primary disease states predisposing a patient to MA include long-term dialysis treatment, multiple myeloma, insulin dependence, and occasionally rheumatoid arthritis. Disease processes such as rheumatoid arthritis, myopathy, chondrosarcoma, and several spondyloarthropathies may mimic the signs and symptoms of MA.

The imaging characteristics of MA are frequently nonspecific and must be appropriately contextualized with the patient's medical history. Many imaging findings related to MA may appear quite similar to other musculoskeletal pathologies, such as tenosynovial giant cell tumors, idiopathic carpal tunnel syndrome, and bone mineral loss. Although specific imaging characteristics (in conjunction with anatomical involvement and patient history) may obviate the need for tissue sampling, pathologic confirmation remains the gold standard for diagnosing musculoskeletal amyloidosis. Despite the associated diagnostic challenge, amyloidosis must be identified and treated as soon as possible to preserve the patient's quality of life; therefore, strong attention to detail, a high index of suspicion, and effective interprofessional cooperation are required. 

One of the earliest signs of amyloidosis is declining renal function. The internal medicine physician and nephrologist are essential in correlating the patient's current functional renal status to their medical history. The nephrologist is also critical in the context of long-term dialysis treatment, considering the onset of beta-2 microglobulin amyloidosis approaches near certainty by the second decade of dialysis treatment. The family medicine physician and endocrinologist can provide helpful guidance and surveillance for those patients requiring injectable insulin to ensure that injection site rotation mitigates the risk of insulin-derived amyloidosis and its mimics. The diagnosis of transthyretin amyloidosis prognosticates cardiac involvement, which necessitates cardiologic intervention. 

A consultation with the rheumatologic physician will provide diagnostic clarity regarding arthritides and spondyloarthropathies that mimic amyloidosis. Frequent coexisting anemia and the need for therapeutic intervention with chemotherapy and plasmapheresis will require the expertise of the Hematology/Oncology physician in conjunction with the pharmacist. The involvement of surgical specialties, such as orthopedic surgery and general surgery, is critical in the identification and surgical palliation of the various manifestations and complications of musculoskeletal amyloidosis. Nursing specialties can assist in patient monitoring, provide education, and ensure patient comfort in inpatient and outpatient settings.

Finally, the radiologist plays a pivotal role in reducing the diagnostic uncertainty of musculoskeletal amyloidosis by correlating the imaging findings and extent of the disease with the patient's medical history and obtaining tissue samples for diagnosis and monitoring disease response following an intervention. Early involvement of the radiologist regarding the most appropriate imaging study for the clinical scenario will increase diagnostic efficiency while reducing the patient's exposure to unnecessary radiation. As such, the ACR appropriateness criteria provides ordering guidance for the healthcare provider and represents a meta-analysis of over 6,200 articles and 8,800 recommendations of the most suitable study for the given clinical scenario.[21] [Level 1]

Although musculoskeletal amyloidosis frequently presents a diagnostic dilemma for the treating physician, rapid diagnosis and treatment will improve patient outcomes and quality of life. A multidisciplinary treatment strategy to address the systemic nature of amyloidosis is recommended.

The views expressed herein are those of the author(s) and do not necessarily reflect the official policy or position of the Defense Health Agency, Brooke Army Medical Center, the Department of Defense, nor any agencies under the U.S. Government.